



## **Arbor Biotechnologies to Participate in Upcoming Healthcare Investor Conferences**

**CAMBRIDGE, MA – September 22, 2022** – Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in upcoming healthcare investor conferences in September and October.

### **Conference Details:**

**Event:** Jefferies Cell & Genetic Medicine Summit  
**Date/Time:** Thursday, September 29<sup>th</sup> at 8:30 a.m. ET  
**Location:** New York, NY  
**Format:** Corporate Presentation

**Event:** Chardan 6th Annual Genetic Medicines Conference  
**Date/Time:** Monday, October 3<sup>rd</sup> at 9:30 a.m. ET and 11:30 a.m. ET  
**Location:** New York, NY  
**Format:** Panel and Corporate Presentation, respectively

**Event:** BMO Biopharma Spotlight Series: Gene Editing & Therapeutics  
**Date/Time:** Thursday, October 6<sup>th</sup> at 12:00 p.m. ET  
**Location:** Virtual  
**Format:** Panel

**Event:** Oppenheimer Private Company Showcase  
**Date/Time:** Tuesday, October 18<sup>th</sup> at 2:10 p.m. PT  
**Location:** Palo Alto, CA  
**Format:** Corporate Presentation

A webcast of the Jefferies Cell & Genetic Medicine Summit presentation will be accessible through the News Section of the company's website at [www.arbor.bio](http://www.arbor.bio), with a replay available for 90 days following the event.

### **About Arbor Biotechnologies**

Arbor Biotechnologies is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines. Founded by Feng Zhang, David Walt, David Scott, and Winston Yan, our proprietary discovery engine is focused on discovering genetic editing capabilities spanning knockdowns to whole gene insertions, which has enabled us to generate the most extensive toolbox of proprietary genomic editors in the industry to date. Leveraging our wholly-owned nucleases as the chassis for genetic modification, we can work backward from disease pathology to choose the optimal editing approach that specifically addresses the underlying cause of disease, resulting in a potentially curative medicine for a wider range of genetic disorders. As Arbor continues to advance its pipeline toward the clinic with an initial focus in liver and CNS disease, the Company has also secured several

partnerships around gene editing and *ex vivo* cell therapy programs to broaden the reach of its novel nuclease technology. For more information, visit [arbor.bio](http://arbor.bio).

## **Contacts**

### **Media**

Amy Bonanno, Solebury Strategic Communications  
[abonanno@soleburystrat.com](mailto:abonanno@soleburystrat.com)  
914-450-0349

### **Investor Relations**

Alexandra Roy, Solebury Strategic Communications  
[aroy@soleburystrat.com](mailto:aroy@soleburystrat.com)  
617-221-9197

##